Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a ۱۰-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in ۲۰۲۶ about this still being an issue, is there anything that can be done to prevent this problem from continuing?

Keywords:

Food and Drug Administration (FDA) , Direct-to-Consumer Advertising (DTCA) , Notice of Violations (NOV) , Office of Prescription Drug Promotion (OPDP) , Fair Balance